The Endocrine Society is pushing the obesity field to think bigger. A new scientific statement published in Endocrine Reviews outlines six key research priorities, arguing that weight loss alone is an incomplete measure of success for obesity treatments. With powerful new medicines like GLP-1s reshaping care, researchers say it's time to understand how these drugs affect heart disease, kidney disease, liver disease, arthritis, and cognitive function — outcomes that matter deeply to patients beyond pounds lost.

The statement also highlights the need to understand why patients respond so differently to the same treatments, how to better measure body fat's impact on health, and what the long-term safety profile of newer obesity drugs looks like. To support this work, the Endocrine Society simultaneously launched its Center on Obesity, a hub for members offering educational resources, advocacy updates, and access to the Medicare GLP-1 Bridge program.

Key Takeaways:

• Six research priorities were identified, including pathophysiology of fat regulation, individualized treatment response, and long-term drug safety
• Future research should validate measures beyond BMI, including bone, muscle, and organ health
• A clinical practice guideline on pharmacological obesity management is expected in 2027

Why it matters: As obesity medicines grow more powerful and widespread, clinicians need a fuller picture of their benefits and risks. Redefining success beyond weight loss could reshape how treatments are developed, approved, and prescribed.